Literature DB >> 3409938

Detection of malignant pleural effusions by tumor marker evaluation.

F Pavesi1, M Lotzniker, P Cremaschi, L Marbello, L Acquistapace, R Moratti.   

Abstract

Cytologic examination and determination of tumor markers (PHI, LDH, alpha-1-glycoprotein, alpha-2-HS-glycoprotein, beta 2-microglobulin, ferritin [corrected], sialic acid, IgE, fetoprotein, CEA, beta HCG and beta 1-SP-glycoprotein) were carried out in pleural fluid samples obtained from 70 patients with suspected neoplasia. Tumor markers were also determined in sera. The protein content of all pleural effusions was greater than or equal to 3 g/dl. Patients were grouped according to diagnosis as follows: (a) 42 with neoplastic diseases (7 mesotheliomas and 19 lung, 4 ovarian, 3 breast and 8 miscellaneous cancers), (b) 22 with benign inflammations and (c) 6 with congestive effusions. Of the parameters examined, only CEA and beta-HCG [corrected] gave information that the effusion was probably malignant. Using 6 ng/ml as cut-off for CEA and 10 mIU/ml for beta HCG, the sensitivity was 57.1% and 45.2%, respectively, specificity was 92.8% for both parameters and test efficiency 0.75 and 0.69, respectively. When CEA and beta HCG were considered together sensitivity increased to 73.8% and efficiency to 0.78. CEA and/or beta HCG were positive in the pleural effusions of 19 of the 20 malignant pleural effusions, all with a negative cytologic examination, which subsequently became positive in 8. Because of their high specificity, these two parameters are a useful tool and can be routinely measured to evaluate pleural effusions of dubious origin, even if CEA and beta HCG cannot, on [corrected] their own, define the primary malignancy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409938     DOI: 10.1016/0277-5379(88)90150-2

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  4 in total

1.  Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases.

Authors:  J Mezger; A Calavrezos; P Drings; U Gatzemeier; E Kaukel; N Konietzko; G Koschel; R Lamerz; J von Pawel; W Römer
Journal:  Lung       Date:  1994       Impact factor: 2.584

2.  Tumor-associated antigens in effusions of malignant and benign origin.

Authors:  A Ammon; H Eiffert; S Reil; J H Beyer; M Droese; W Hiddemann
Journal:  Clin Investig       Date:  1993-06

3.  Reactive oxygen metabolites can be used to differentiate malignant and non-malignant pleural efffusions.

Authors:  Ufuk Cobanoglu; Fuat Sayir; Duygu Mergan
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

4.  The search for tumor-associated proteins in pleural effusions by means of monoclonal antibodies and a dot blot assay.

Authors:  M Lawniczak; J Sikora; P Kania; J Zeromski
Journal:  Lung       Date:  1992       Impact factor: 2.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.